Drug–induced gingival overgrowth after cyclosporin A therapy

Authors

  • Miłosz Ambicki Clinical Department of Maxillo-Facial Surgery, Frederic Chopin Provincial Specialist Hospital in Rzeszów
  • Robert Brodowski Clinical Department of Maxillo-Facial Surgery, Frederic Chopin Provincial Specialist Hospital in Rzeszów
  • Marta Mucha Clinical Department of Maxillo-Facial Surgery, Frederic Chopin Provincial Specialist Hospital in Rzeszów
  • Małgorzata Migut Clinical Department of Maxillo-Facial Surgery, Frederic Chopin Provincial Specialist Hospital in Rzeszów; Department of Emergency Medicine, Faculty of Medicine, the University of Rzeszów
  • Adam Malawski-Róg Clinical Department of Maxillo-Facial Surgery, Frederic Chopin Provincial Specialist Hospital in Rzeszów
  • Wojciech Stopyra Clinical Department of Maxillo-Facial Surgery, Frederic Chopin Provincial Specialist Hospital in Rzeszów
  • Bogumił Lewandowski Clinical Department of Maxillo-Facial Surgery, Frederic Chopin Provincial Specialist Hospital in Rzeszów; Department of Emergency Medicine, Faculty of Medicine, the University of Rzeszów https://orcid.org/0000-0002-8045-5093

DOI:

https://doi.org/10.15584/ejcem.2017.1.13

Keywords:

drug-induced gingival overgrowth, cyclosporin a, gingivitis, transplant

Abstract

Introduction. Drug–induced gingival overgrowth is a condition caused by side effects of treatment with one of three types of drugs: phenytoin (used in epilepsy treatment), cyclosporin A (used in transplantology after allogeneic organ transplants) and calcium channel blockers (in the treatment of hypertension). Gingival overgrowth leads to the development of inflammation within the gums and periodontium, reduced comfort in a patient’s life, and consequently even loss of teeth.

Aim. The aim of this study was to present the issue of drug–induced gingival overgrowth based on a review of the literature and observations of patients treated in the Clinical Department of Maxillo-Facial Surgery, Frederic Chopin Provincial Specialist Hospital in Rzeszów.

Case description. Massive gingival overgrowth requires surgical management. Attention should be paid to multidisciplinary cooperation in case of patients qualified for a transplant. It is also important to qualify and evaluate the state of the oral cavity prior to the implementation of immunosuppressive medication, instruction of patients on oral hygiene and removal of the outbreaks of infection.

Downloads

Download data is not yet available.

References

Lipska W, Gałecka-Wanatowicz D, Chomyszyn-Gajewska M. Przerostowe zapalenie dziąseł – opis przypadków. Implantoprotetyka 2009; X,4(37):44-47.

Radwan-Oczko M, Ziętek M, Boratyńska M, Konopka T. Stopień i rozległość przerostu dziąseł u chorych po przeszczepie nerki leczonych cyklosporyną A. Czas Stomat 1996,49:824-829.

Jańczuk Z. Praktyczna periodontologia kliniczna. Warszawa: Kwintesencja;2004.

Wolf HF, Rateitschak EM, Rateitschak KH. Periodontologia. Warszawa: Czelej;2006.

Kowalski J. Lekopochodny przerost dziąseł – przegląd literatury. Nowa Stomat 2010;4:180-182.

Seymour RA, Elis JS, Thomason JM. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000; 27:217-223.

Gaphor SM, Abdulkareem SA, Abdullah MJ. Cyclosporine induced gingival hyperplasia in kidney transplant: a case report and review of the literature. European Scientific Journal 2014; 10(15):1857 – 7881.

Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996;23:165-175.

Gonzales FJ. Human cytochromes p450: problems and prospects. Trends Pharmacol Scienc 1992; 13:346-352.

Tyrzyk S, Sadlak-Nowicka J, Bochniak M, Kędzia A, Szumska-Tyrzyk B, Rutkowski P. Obraz kliniczny, radiologiczny i bakteriologiczny przyzębia u chorych leczonych cyklosporyną A po przeszczepie nerki. Dent Med Probl 2002; 39(1):55-62.

Olczak-Kowalczyk D, Bedra B, Śmirska E, Pawłowska J, Grenda R. Zmiany w jamie ustnej u pacjentów po transplantacji narządów unaczynionych w zależności od rodzaju stosowanej

Marshall RI, Bartold PM. Medication induced gingival overgrowth. Oral Diseaes 1998;4:130-151.

Vescovi P, Meleti M, Manfredi M, Bonanini M. Pathogenesis of cyclosporin induced gingival overgrowth. Min Stomatol 2003; 52:219-229.

Ciavarella D, Guiglia R, Campisi G et.al. Update on gingival overgrowth by cyclosporine A in renal transplants. Med Oral Patol Cir Bucal 2007;12:19-25.

Węgorska D, Syryńska M. Przerosty dziąseł – Gingivitis hyperplastica – jako efekt uboczny leczenia cyklosporyną A (CsA, CyA0). Magazyn Stomat 1994;4(1):18-21.

Prajs K, Fliciński J, Przepiera-Będziak H, Brzosko I, Ostanek L. Działania niepożądane w czasie leczenia cyklosporyną A u chorych na reumatoidalne zapalenie stawów – obserwacje własne. Roczniki Pomorskiej Akademii Medycznej w Szczecinie 2010; 56(1):48-51.

Camargo PM, Melnick PR, Pirih FQ, Lagos R, Takei. Treatment of drug-induced gingival enlargement: H. Aesthetic and functional considerations. Periodontology 2001;27:131-138.

Downloads

Published

2017-03-31

How to Cite

Ambicki, M., Brodowski, R., Mucha, M., Migut, M., Malawski-Róg, A., Stopyra, W., & Lewandowski, B. (2017). Drug–induced gingival overgrowth after cyclosporin A therapy. European Journal of Clinical and Experimental Medicine, 15(1), 82–86. https://doi.org/10.15584/ejcem.2017.1.13

Issue

Vol. 15 No. 1 (2017): European Journal of Clinical and Experimental Medicine

Section

CASUISTIC PAPERS

License

Copyright (c) 2017 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.

Most read articles by the same author(s)